RxDoctor Payments Data

Kimberly Baldock, MD

Internal Medicine · Ashland, KYNPI 1144225657

Payments from drug & device makers

$584in general payments, 2019–2025

Across 33 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$256
  • AbbVie$167
  • Amgen$37
  • Axsome Therapeutics, Inc.$35
  • Takeda Pharmaceuticals U.S.A., Inc.$25
  • Coloplast$23
  • plus $41 from 3 others

What the payments were for

  • Food & beverage$584100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$584 in reported general payments places this provider in the 55th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$146,153
Medicare patients
302
Services billed
2,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide204$242,531
TrulicityDulaglutide119$181,570
JardianceEmpagliflozin142$169,975
EliquisApixaban148$142,041
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$56,253
MounjaroTirzepatide43$53,292
RybelsusSemaglutide22$42,676
WegovySemaglutide27$36,955
JanuviaSitagliptin Phosphate30$32,072
XareltoRivaroxaban38$31,793
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog53$31,101
FarxigaDapagliflozin Propanediol25$29,632
Breo ElliptaFluticasone/Vilanterol45$27,110
EntrestoSacubitril/Valsartan30$25,518
LinzessLinaclotide23$24,436

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$14$322,163253 claims
GSKTrelegy Ellipta, Breo Ellipta$256$83,36495 claims
AbbVieLinzess, Synthroid$167$34,085287 claims
MerckJanuvia$13$32,07230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Ashland

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →